- Home
- TARS
TARS
Tarsus Pharmaceuticals Inc.
as 05-09-2025 4:00pm EST
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | $66.33 | AVG Volume (30 days): | 645.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.08 - $57.28 | Next Earning Date: | 05-01-2025 |
| Revenue: | $233,674,000 | Revenue Growth: | 449.03% |
| Revenue Growth (this year): | 103.68% | Revenue Growth (next year): | 45.73% |
Stock Insider Trading Activity of Tarsus Pharmaceuticals Inc. (TARS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 24 '25 | Sell | $50.00 | 6,000 | $300,000.00 | 824,106 | |
| Wahl Bryan | TARS | General Counsel | Mar 18 '25 | Sell | $47.93 | 9,686 | $463,765.53 | 51,712 | |
| Whitfield Dianne C. | TARS | Chief Human Resources Officer | Mar 18 '25 | Sell | $47.93 | 6,711 | $321,323.02 | 50,751 | |
| Neervannan Seshadri | TARS | Chief Operating Officer | Mar 18 '25 | Sell | $47.93 | 7,583 | $363,141.50 | 84,660 | |
| Farrow Jeffrey S | TARS | See Remarks | Mar 18 '25 | Sell | $47.93 | 3,724 | $178,306.42 | 24,871 | |
| Mottiwala Aziz | TARS | Chief Commercial Officer | Mar 18 '25 | Sell | $47.93 | 10,565 | $505,856.42 | 65,057 | |
| Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 18 '25 | Sell | $47.93 | 24,216 | $1,163,050.13 | 824,106 |
Latest Tarsus Pharmaceuticals Inc. News
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Tarsus to Participate in Upcoming Investor Conferences
Insider Monkey
4 days ago
Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts
Simply Wall St.
6 days ago
Analysts Just Made A Substantial Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Forecasts
GuruFocus.com
8 days ago
Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ...
Zacks
8 days ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
8 days ago
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Zacks
9 days ago
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
Zacks
14 days ago
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Compare TARS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.